Neupath Health Inc. · TSXV:NPTH
Neupath Health — Investor Presentation (May 2025)
19 slides from Neupath Health's investor presentation, May 2, 2025
Slide 1: Investor Update Spring 2025
Investor Update Spring 2025 Growing Canada’s Largest Network of Chronic Pain Treatment Facilities (All figures in C$ unless otherwise indicated)
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation are forward looking statements which may include, but are not limited to, statements with respect to the future financial or operating performance of NeuPath and its projects, the market conditions, business strategy, corporate plans
Slide 3: Non-IFRS Financial Measures
Non-IFRS Financial Measures This presentation makes reference to certain financial measures, including non-IFRS financial measures that are historical and non-GAAP or non-GAAP ratios. Management uses these financial measures for purposes of comparison to prior periods and development of future proje
Slide 4: Growing Canada's Leader in Chronic Pain Treatment
Growing Canada’s Leader in Chronic Pain Treatment NeuPath (TSXV:NPTH) is a private provider of public health, operating a growing network of chronic pain treatment facilities. Large need, growing market Multiple organic and inorganic growth opportunities Regulated medical facilities, specializ
Slide 5: Patient-Centred Multidisciplinary Care Model
Patient-Centred Multidisciplinary Care Model Key Metrics Wide range of specialties ~ 200,000 patient visits annually Physiatrists ~154 healthcare professionals, incl. ~100 Anaesthesiologists MDs Orthopaedic surgeons ~15,000 referring physicians General practitioners with specialized tr
Slide 6: Reaching Patients in High-Growth Regions
Reaching Patients in High-Growth Regions NeuPath operates the largest network for chronic pain facilities in Canada • Currently addressing ~67% and ~38% of Ontario and Alberta’s population, respectively • Planning expansion in existing and new high-growth regions across Canada Alberta Southern Ontar
Slide 7: Growing Revenue and Cashflows…
Growing Revenue and Cashflows… 8% 29% CAGR CAGR $3.8 $80 $72.8 $66.1 Ongoing $3.2 $70 $62.7 Growth of $60 expansion in Adj EBITDA existing and $2.3 reflects $50 new markets investments and $40 is expected operational $30 to continue improvements $20 revenue to better serve $10 growth more patients $
Slide 8: …while decreasing facilities footprint…
…while decreasing facilities footprint… -26% Improving Capacity Utilization 75% vs. 68% (For the year ended Dec 31, 2024 vs prior year) Dec/23 Dec/24 Dec/25e Total Sq Ft Under Lease at Year End (incl sublease) 8
Slide 9: …driving a Balance Sheet Turnaround
…driving a Balance Sheet Turnaround $8.0 $7.0 $6.8 $6.1 $5.9 $6.0 $5.3 Nearly 50% $5.0 reduction in net $4.0 $3.8 debt $3.2 $3.2 while investing $2.9 $2.9 $3.0 $3.0 in new facilities $2.3 (including three new $2.0 $1.5 fluoroscopy suites $1.0 in 2024) $0.0 Cash Debt* Net Debt* Adj EBITDA Q4/22 Q4/23
Slide 10: New Credit Facility To Drive Growth
New Credit Facility To Drive Growth Flexibility to respond to opportunities: Well-positioned to accelerate growth in 2025 and beyond New $13.5 million National Bank of Canada (NB) facility o $6.5 million non-revolving term loan “credit” facility to refinance all LTD o $4.0 million “revolving” cred
Slide 11: Multiple Avenues for Organic and Inorganic Growth
Multiple Avenues for Organic and Inorganic Growth 3. Expand Through Adjacent Markets 2. Expand Our 1. Increase Capacity Network Utilization in Existing Orthopedics & specialties Facilities with high overlapping Build-out a pan-Canadian patient cohorts national network through Onboard new docto
Slide 12: Key Growth Driver: Attracting and Retaining Physicians
Key Growth Driver: Attracting and Retaining Physicians Regulated treatment facilities Access to new technologies, modern equipment Built in referral network to rapidly build practice HR, IT and administration handled by NeuPath Network allows for flexible work arrangements Excellent work
Slide 13: Expanding Treatment Options
Expanding Treatment Options First to Launch Arthrosamid® in N. America Novel Treatment Option for Osteoarthritis of the Knee Worked with Contura to train physicians and make this new treatment available Currently available at five Ontario locations o Adding new Ontario locations and our Albert
Slide 14: Capitalization & Financial Data
Capitalization & Financial Data Financial Information Capital Structure Tight capital structure Common Shares Outstanding 56,154,491 34% institutional ownership Dilutive Instruments Majority held by close investors Warrants Outstanding(1) 5,270,138 Since joining NeuPath, CEO has Stock Option
Slide 15: Experienced Leadership
Experienced Leadership Joined the Board of Directors in 2020, became CEO in Sept. 2022 25 years in biopharma; including Clementia Pharmaceuticals, Joseph Walewicz MethylGene, Warnex, Paladin Labs CEO MBA, Finance from McGill, CFA charterholder Joined as Corporate Controller in 2019, promoted to
Slide 16: Since BBHCC 2024
Since BBHCC 2024 Record revenues of $72.8 million in 2024, up 10%, by serving more patients Record adj EBITDA of $3.8 million, up 19% year-over-year, reflecting ongoing operational improvements In Q1 2025 performed the first-ever injection in North America of Arthrosamid® (2.5% iPAAG) at its M
Slide 17: Key Takeaways: Multiple Drivers of Shareholder Value
Key Takeaways: Multiple Drivers of Shareholder Value Successful turnaround – growing top line and adj EBITDA, improving margins and emerging profitability Well-aligned with government policy and recent initiatives Multiple paths for growth Demand for chronic pain treatment rising Significa
Slide 18: EBITDA Reconciliation of IFRS
EBITDA Reconciliation of IFRS EBITDA and Adjusted EBITDA EBITDA refers to net income (loss) determined in accordance with IFRS, before depreciation and amortization, net interest expense (income) and income tax expense (recovery). The Company defines adjusted EBITDA, as EBITDA, excluding stock-based
Slide 19: Thank you!
ee NeuPath ‘:.: Health Inc. & Thank you! : TSXV: NPTH